Pharma Price Probes To Persist With Or Without Shkreli
This article was originally published in Scrip
While Martin Shkreli, who was arrested last week and charged with fraud and misappropriating funds, is gone as CEO of Turing Pharmaceuticals AG – ousted on Dec. 18, with the company's chairman, Ron Tilles, taking over as interim chief – the hellfire over drug pricing he helped to reignite when he jacked up the price of Daraprim (pyrimethamine) by more than 5,000% is nowhere near cooling down.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.